CORPHED Drug Patent Profile
Which patents cover Corphed, and what generic alternatives are available?
Corphed is a drug marketed by Chartwell Rx and Ph Health and is included in two NDAs.
The generic ingredient in CORPHED is ephedrine sulfate. There are two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Corphed
A generic version of CORPHED was approved as ephedrine sulfate by SANDOZ on August 23rd, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CORPHED?
- What are the global sales for CORPHED?
- What is Average Wholesale Price for CORPHED?
Summary for CORPHED
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 8 |
| DailyMed Link: | CORPHED at DailyMed |
US Patents and Regulatory Information for CORPHED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | CORPHED | pseudoephedrine hydrochloride; triprolidine hydrochloride | TABLET;ORAL | 088602-001 | Apr 11, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ph Health | CORPHEDRA | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208943-001 | Jan 27, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
